Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838915 | 0.88 | HRH3 (0.46) | HRH3ALDH1A1KMT2AL3MBTL1MEN1 | |
| SCHEMBL13838900 | 0.84 | HPGD (0.61) | AOC3HRH3ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL13838928 | 0.81 | AOC3 (0.41) | AOC3HRH3ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL13838918 | 0.81 | HRH3 (0.44) | AOC3VNN1HRH3ALDH1A1KMT2A | |
| SCHEMBL13838920 | 0.80 | HRH3 (0.43) | AOC3HRH3ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL3811818 | 0.80 | AOC3 (0.40) | AOC3VNN1HRH3ALDH1A1KMT2A | |
| SCHEMBL3808815 | 0.79 | HSD11B1 (0.48) | AOC3HRH3KMT2AMEN1HPGD | |
| SCHEMBL13838922 | 0.79 | HRH3 (0.43) | AOC3HRH3ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL20236803 | 0.78 | ALDH1A1 (0.59) | HRH3ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL20236802 | 0.78 | KMT2A (0.47) | AOC3HRH3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD11B2, HSD3B1 | AOC3 3126/4885VNN1 2070/4885HRH3 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.